We were able to show that each myDC subtype (both the complete CD11c+ population, as well as the BDCA-1+ and BDCA-3+ subsets separately) was capable to engulf melanoma cells with a trend towards higher uptake by BDCA-3+ DC which is expected as these cells are specialized in cross-presentation of (tumor) antigens (40). The gene discussed is ITGAX; the disease is melanoma.